Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team

Jørgen Vestbo, Alvar Agusti, Emiel F.M. Wouters, Per Bakke, Peter M.A. Calverley, Bartolome Celli, Harvey Coxson, Courtney Crim, Lisa D. Edwards, Nicholas Locantore, David A. Lomas, William MacNee, Bruce Miller, Stephen I. Rennard, Edwin K. Silverman, Julie C. Yates, Ruth Tal-Singer

Research output: Contribution to journalReview article

100 Citations (Scopus)

Abstract

Rationale: Chronic obstructive pulmonary disease (COPD) seems to be a heterogeneous disease with a variable course. Objectives: We wished to characterize the heterogeneity and variability of COPD longitudinally. Methods: In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study of 2,164 patients with clinically stableCOPD, 337smokerswithnormal lung function, and 245 never-smokers, we measured a large number of clinical parameters, lung function, exercise tolerance, biomarkers, andamount ofemphysema by computed tomography. All three groups were followed for 3 years. Measurements and Main Results: We found a striking heterogeneity among patients with COPD, with poor correlations between FEV1, symptoms, quality of life, functional outcomes, and biomarkers. Presence of systemic inflammation was found in only a limited proportion of patients, and did not relate to baseline characteristics or disease progression, but added prognostic value for predicting mortality. Exacerbations tracked over time and added to the conceptof the "frequent exacerbatorphenotype." Disease coursewasvery variable,with close to a third of patients not progressing at all.Risk factors for 3-year change in both FEV1 and lung density were assessed. For FEV1 decline, continued smoking and presence of emphysema were the strongest predictors of progression; club cell protein was found to be a potential biomarker for disease activity. For progression ofemphysema, the strongest predictors were continued smoking and female sex. Conclusions: By following a large, well characterized cohort of patients with COPD over 3 years, we have a clearer picture of a heterogeneous disease with clinically important subtypes ("phenotypes" ) and a variable and not inherently progressive course. Clinical trial registered with www.clinicaltrials.gov (NCT00292552).

Original languageEnglish (US)
Pages (from-to)1022-1030
Number of pages9
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume189
Issue number9
DOIs
StatePublished - May 1 2014

Fingerprint

Chronic Obstructive Pulmonary Disease
Biomarkers
Lung
Smoking
Exercise Tolerance
Emphysema
Disease Progression
Tomography
Quality of Life
Clinical Studies
Clinical Trials
Inflammation
Phenotype
Mortality
Proteins

Keywords

  • Chronic obstructive pulmonary disease
  • Comorbidities
  • Computed tomography lung density
  • Exacerbations
  • Lung function

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. / Vestbo, Jørgen; Agusti, Alvar; Wouters, Emiel F.M.; Bakke, Per; Calverley, Peter M.A.; Celli, Bartolome; Coxson, Harvey; Crim, Courtney; Edwards, Lisa D.; Locantore, Nicholas; Lomas, David A.; MacNee, William; Miller, Bruce; Rennard, Stephen I.; Silverman, Edwin K.; Yates, Julie C.; Tal-Singer, Ruth.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 189, No. 9, 01.05.2014, p. 1022-1030.

Research output: Contribution to journalReview article

Vestbo, J, Agusti, A, Wouters, EFM, Bakke, P, Calverley, PMA, Celli, B, Coxson, H, Crim, C, Edwards, LD, Locantore, N, Lomas, DA, MacNee, W, Miller, B, Rennard, SI, Silverman, EK, Yates, JC & Tal-Singer, R 2014, 'Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team', American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 9, pp. 1022-1030. https://doi.org/10.1164/rccm.201311-2006PP
Vestbo, Jørgen ; Agusti, Alvar ; Wouters, Emiel F.M. ; Bakke, Per ; Calverley, Peter M.A. ; Celli, Bartolome ; Coxson, Harvey ; Crim, Courtney ; Edwards, Lisa D. ; Locantore, Nicholas ; Lomas, David A. ; MacNee, William ; Miller, Bruce ; Rennard, Stephen I. ; Silverman, Edwin K. ; Yates, Julie C. ; Tal-Singer, Ruth. / Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. In: American Journal of Respiratory and Critical Care Medicine. 2014 ; Vol. 189, No. 9. pp. 1022-1030.
@article{38a929cc67a0497ea9ab2b8d97a3210b,
title = "Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team",
abstract = "Rationale: Chronic obstructive pulmonary disease (COPD) seems to be a heterogeneous disease with a variable course. Objectives: We wished to characterize the heterogeneity and variability of COPD longitudinally. Methods: In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study of 2,164 patients with clinically stableCOPD, 337smokerswithnormal lung function, and 245 never-smokers, we measured a large number of clinical parameters, lung function, exercise tolerance, biomarkers, andamount ofemphysema by computed tomography. All three groups were followed for 3 years. Measurements and Main Results: We found a striking heterogeneity among patients with COPD, with poor correlations between FEV1, symptoms, quality of life, functional outcomes, and biomarkers. Presence of systemic inflammation was found in only a limited proportion of patients, and did not relate to baseline characteristics or disease progression, but added prognostic value for predicting mortality. Exacerbations tracked over time and added to the conceptof the {"}frequent exacerbatorphenotype.{"} Disease coursewasvery variable,with close to a third of patients not progressing at all.Risk factors for 3-year change in both FEV1 and lung density were assessed. For FEV1 decline, continued smoking and presence of emphysema were the strongest predictors of progression; club cell protein was found to be a potential biomarker for disease activity. For progression ofemphysema, the strongest predictors were continued smoking and female sex. Conclusions: By following a large, well characterized cohort of patients with COPD over 3 years, we have a clearer picture of a heterogeneous disease with clinically important subtypes ({"}phenotypes{"} ) and a variable and not inherently progressive course. Clinical trial registered with www.clinicaltrials.gov (NCT00292552).",
keywords = "Chronic obstructive pulmonary disease, Comorbidities, Computed tomography lung density, Exacerbations, Lung function",
author = "J{\o}rgen Vestbo and Alvar Agusti and Wouters, {Emiel F.M.} and Per Bakke and Calverley, {Peter M.A.} and Bartolome Celli and Harvey Coxson and Courtney Crim and Edwards, {Lisa D.} and Nicholas Locantore and Lomas, {David A.} and William MacNee and Bruce Miller and Rennard, {Stephen I.} and Silverman, {Edwin K.} and Yates, {Julie C.} and Ruth Tal-Singer",
year = "2014",
month = "5",
day = "1",
doi = "10.1164/rccm.201311-2006PP",
language = "English (US)",
volume = "189",
pages = "1022--1030",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "9",

}

TY - JOUR

T1 - Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team

AU - Vestbo, Jørgen

AU - Agusti, Alvar

AU - Wouters, Emiel F.M.

AU - Bakke, Per

AU - Calverley, Peter M.A.

AU - Celli, Bartolome

AU - Coxson, Harvey

AU - Crim, Courtney

AU - Edwards, Lisa D.

AU - Locantore, Nicholas

AU - Lomas, David A.

AU - MacNee, William

AU - Miller, Bruce

AU - Rennard, Stephen I.

AU - Silverman, Edwin K.

AU - Yates, Julie C.

AU - Tal-Singer, Ruth

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Rationale: Chronic obstructive pulmonary disease (COPD) seems to be a heterogeneous disease with a variable course. Objectives: We wished to characterize the heterogeneity and variability of COPD longitudinally. Methods: In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study of 2,164 patients with clinically stableCOPD, 337smokerswithnormal lung function, and 245 never-smokers, we measured a large number of clinical parameters, lung function, exercise tolerance, biomarkers, andamount ofemphysema by computed tomography. All three groups were followed for 3 years. Measurements and Main Results: We found a striking heterogeneity among patients with COPD, with poor correlations between FEV1, symptoms, quality of life, functional outcomes, and biomarkers. Presence of systemic inflammation was found in only a limited proportion of patients, and did not relate to baseline characteristics or disease progression, but added prognostic value for predicting mortality. Exacerbations tracked over time and added to the conceptof the "frequent exacerbatorphenotype." Disease coursewasvery variable,with close to a third of patients not progressing at all.Risk factors for 3-year change in both FEV1 and lung density were assessed. For FEV1 decline, continued smoking and presence of emphysema were the strongest predictors of progression; club cell protein was found to be a potential biomarker for disease activity. For progression ofemphysema, the strongest predictors were continued smoking and female sex. Conclusions: By following a large, well characterized cohort of patients with COPD over 3 years, we have a clearer picture of a heterogeneous disease with clinically important subtypes ("phenotypes" ) and a variable and not inherently progressive course. Clinical trial registered with www.clinicaltrials.gov (NCT00292552).

AB - Rationale: Chronic obstructive pulmonary disease (COPD) seems to be a heterogeneous disease with a variable course. Objectives: We wished to characterize the heterogeneity and variability of COPD longitudinally. Methods: In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study of 2,164 patients with clinically stableCOPD, 337smokerswithnormal lung function, and 245 never-smokers, we measured a large number of clinical parameters, lung function, exercise tolerance, biomarkers, andamount ofemphysema by computed tomography. All three groups were followed for 3 years. Measurements and Main Results: We found a striking heterogeneity among patients with COPD, with poor correlations between FEV1, symptoms, quality of life, functional outcomes, and biomarkers. Presence of systemic inflammation was found in only a limited proportion of patients, and did not relate to baseline characteristics or disease progression, but added prognostic value for predicting mortality. Exacerbations tracked over time and added to the conceptof the "frequent exacerbatorphenotype." Disease coursewasvery variable,with close to a third of patients not progressing at all.Risk factors for 3-year change in both FEV1 and lung density were assessed. For FEV1 decline, continued smoking and presence of emphysema were the strongest predictors of progression; club cell protein was found to be a potential biomarker for disease activity. For progression ofemphysema, the strongest predictors were continued smoking and female sex. Conclusions: By following a large, well characterized cohort of patients with COPD over 3 years, we have a clearer picture of a heterogeneous disease with clinically important subtypes ("phenotypes" ) and a variable and not inherently progressive course. Clinical trial registered with www.clinicaltrials.gov (NCT00292552).

KW - Chronic obstructive pulmonary disease

KW - Comorbidities

KW - Computed tomography lung density

KW - Exacerbations

KW - Lung function

UR - http://www.scopus.com/inward/record.url?scp=84899784758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899784758&partnerID=8YFLogxK

U2 - 10.1164/rccm.201311-2006PP

DO - 10.1164/rccm.201311-2006PP

M3 - Review article

C2 - 24552242

AN - SCOPUS:84899784758

VL - 189

SP - 1022

EP - 1030

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 9

ER -